This finding is clinically relevant especially in light of recent findings showing that AD patients with very high levels of CSF tau and phosphorylated tau at threonine 181 (p-tau181) exhibit worse clinical outcomes over time, including faster progression of cognitive deficits and a higher mortality5. The gene discussed is MAPT; the disease is Alzheimer disease.